Back to top

biotechs: Archive

Zacks Equity Research

RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program

Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.

BAYRYPositive Net Change VRNAPositive Net Change RXRXPositive Net Change RLYBNegative Net Change

Ahan Chakraborty

Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.

NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change

Zacks Equity Research

Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?

BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.

RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change

Kinjel Shah

GSK's Specialty Medicines Unit on a Strong Footing: Here's Why

GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

SNYPositive Net Change AZNPositive Net Change GSKPositive Net Change MRKPositive Net Change

Zacks Equity Research

Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck

VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.

SNYPositive Net Change MRKPositive Net Change LLYPositive Net Change VRNAPositive Net Change

Zacks Equity Research

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success

Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.

BAYRYPositive Net Change COGTPositive Net Change VRNAPositive Net Change IMCRPositive Net Change

Zacks Equity Research

MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy

Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.

BAYRYPositive Net Change MBIOPositive Net Change VRNAPositive Net Change IMCRPositive Net Change

Zacks Equity Research

DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review

Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status.

SNYPositive Net Change BIIBNegative Net Change DNLIPositive Net Change

Zacks Equity Research

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change

Sundeep Ganoria

How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?

ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.

JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change

Ahan Chakraborty

Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?

Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.

SDGRPositive Net Change RLAYPositive Net Change RXRXPositive Net Change

Zacks Equity Research

Intellia Gains 29.8% in a Month: How Should You Play the Stock?

NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.

REGNPositive Net Change VRTXPositive Net Change NTLAPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?

EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.

BMYPositive Net Change MRKPositive Net Change EXELPositive Net Change

Zacks Equity Research

SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca

Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.

AZNPositive Net Change BMYPositive Net Change MRKPositive Net Change SMMTPositive Net Change

Zacks Equity Research

PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?

Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.

RHHBYPositive Net Change BMYPositive Net Change NVOPositive Net Change PRTAPositive Net Change

Ahan Chakraborty

Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

NVOPositive Net Change MRKPositive Net Change LLYPositive Net Change

Sraddha Singha

Will Semiconductor and Biotech Drive EMCOR's Bookings?

EMCOR hits record RPOs as CHIPS and IRA acts drive long-term demand across semiconductor and biotech markets.

ACMPositive Net Change KBRPositive Net Change EMEPositive Net Change

Zacks Equity Research

AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

AZNPositive Net Change EXELPositive Net Change PBYIPositive Net Change SPROPositive Net Change

Sundeep Ganoria

Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.

JAZZPositive Net Change AXSMPositive Net Change HRMYPositive Net Change

Zacks Equity Research

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study

NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.

NVSPositive Net Change BAYRYPositive Net Change VRNAPositive Net Change IMCRPositive Net Change

Zacks Equity Research

Will The Decline in Legacy Drugs Pull Down BMY's Top Line?

Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.

BMYPositive Net Change PFENegative Net Change MRKPositive Net Change

Zacks Equity Research

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

REGNPositive Net Change NVSPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change

Zacks Equity Research

MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

GSKPositive Net Change PFENegative Net Change MRNAPositive Net Change

Zacks Equity Research

Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore

EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.

ALKSPositive Net Change EXELPositive Net Change VRNAPositive Net Change KNSAPositive Net Change

Sundeep Ganoria

Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

MRKPositive Net Change LLYPositive Net Change ABBVPositive Net Change